The Pharma Data

MARCH 23, 2022

In fact, antiviral therapies designed to treat viruses such as hepatitis C (Sofosbuvir/SOVALDI) work by blocking viral polymerase. Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase.

Protein 52

Protein Genome Genomics Research 52

Delveinsight

FEBRUARY 9, 2021

Breyanzi will come with a price tag of USD 410,300 wholesale price, said the company, justifying it after taking into consideration several factors including medical and clinical value, patient value, and societal value. The nod came a few months after the CHMP opinionated positively for the same.

FDA Approval 52

FDA Approval Marketing Research Protein 52

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Hristo Svilenov, PhD, Associate Professor, Ghent University, on: ‘Extrinsic stabilisation of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2’. He will present on science and risk-based shelf-life prediction for protein biologics.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

The luncheon presentations include: Matthias Hillenbrand, PhD, Head, Infectious Disease Research & Biosafety Officer, Memo Therapeutics, on: ‘Best in class antiviral antibodies from cognate recombinant antibody repertoires of human donors’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

MAY 4, 2021

to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 EXECUTIVE COMMENTARY.

Vaccination 40

Vaccination Vaccine Production Sales 40